

### INTERNATIONAL CONGRESS

# **MULTIPLE MYELOMA**

and related malignancies
7" Edition

November 7-9, 2024
The Nicolaus Hotel, Bari (Italy)

Presidents and Scientific Responsibles Prof. Angelo Vacca, Prof. Roberto Ria

#### **PRESENTATION**

In the last 20 years remarkable advancements in the understanding of the pathophysiology of multiple myeloma and related malignancies have paved the way to the identification and the subsequent adoption of new effective and safe therapies. Following the 6th edition which was held on November 5-7th, 2020, the time has come for a thorough biological and clinical update. Like in the previous editions, we aim to provide hematologists, oncologists, internists, radiologists, and other medical specialists as well as young researchers, residents, doctoral and undergraduate students with an invaluable opportunity to deepen and update their knowledge on the already acquired and emerging developments in the biology and treatment of multiple myeloma and related malignancies.

A number of internationally renowned speakers have been invited to deliver state-of-the-art lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic markers and novel approaches to assess the response to therapy, new single or combined therapeutic molecules specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation, bispecific monoclonal antibodies, and CAR-T cells will also be the object of intensive scrutiny. Finally, supportive therapy, emerging toxicity, and infectious complications will be discussed in their many facets.

We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by multiple myeloma and cognate tumors may now be approached with more rational and more effective achievements.

Angelo Vacca and Roberto Ria

### **PROGRAMME**

## Thursday, November 7, 2024

13.30-14.15	Registration of participants
14.15-14.30	Welcome speech and orientation  Angelo Vacca, Roberto Ria
14.30-15.10	Opening Lecture Chairperson: Angelo Vacca (Bari, IT)
	Role of the immune microenviroment in resistance to T-cell based therapies  Paola Neri (Calgary, CAN)
15.10-17.15	Workshop 1 Biology: Genomic, Epigenomic and Proteomic of Multiple Myeloma and Precursors Chairpersons: Niccolò Bolli (Milano, IT), Andrzej J Jakubowiak (Poznan, PL)
15.10-15.35	The supportive role of the endothelial niche in myeloma biology Aldo M. Roccaro (Brescia, IT)
15.35-16.00	Mitochondrial dysfunctions in multiple myeloma Nicola Amodio (Catanzaro, IT)
16.00-16.25	Genomic complexity during smoldering multiple myeloma progression  Matteo Da Vià (Milano, IT)
16.25-16.50	Transcriptome of multiple myeloma  Anja Seckinger (Jette, BE)
16.50-17.15	Circulating tumor cells in multiple myeloma  Andrzej J Jakubowiak (Poznan, PL)
17.15-17.30	Coffee break
17.30-19.35	Workshop 2 Biology: Bone Disease and Immunodeficiency in Myeloma Chairperson: Tom Cupedo (Rotterdam, NL), Karin Vanderkerken (Brussels, B)
17.30-17.55	New acquisition on myeloma bone disease pathogenesis  Nicola Giuliani (Parma, IT)
17.55-18.20	Dendritic cells in Multiple Myeloma  Kim De Veirman (Brussels, B)

18.20-18.45	Impact of the gut microbiota and motility on myeloma immunity  Matteo Bellone (Milan, IT)		
18.45-19.10	The tumor-supportive microenvironment in multiple myeloma  Tom Cupedo (Rotterdam, NL)		
19.10-19.35	Mesenchymal stem cells in Multiple Myeloma  Ivan Van Riet (Brussels, B)		
Friday, November 8, 2024			
08.30-11.00	Workshop 3 Prognostic Stratification and Big Data Chairpersons: Mattia D'Agostino, Ella Willenbacher (Innsbruck, AT)		
08.30 - 08.55	Impact of genomic complexity on prognosis of multiple myeloma Niccolò Bolli (Milan, IT)		
08.55 - 09.20	Unraveling the biological underpinnings: Prognostic stratification of smoldering multiple myeloma Annamaria Gullà (Candiolo, IT)		
09.20 - 09.45	1q abnormalities for multiple myeloma risk stratification  Mattia D'Agostino (Torino)		
09.45 - 10.10	Next generation sequencing or next generation flow for MRD evaluation Carolina Terragna (Bologna, IT)		
10.10 - 10.35	Role of registry to increase knowledge on multiple myeloma Wolfgang Willenbacher (Innsbruck, AT)		
10.35 – 11.00	High risk disease beyond CAR-T and BiTEs: Machine learning guided approaches Antonio Giovanni Solimando (Bari, IT)		
11.00-11.20	Coffee break		
11.20-13.00	Workshop 4 Clinical Features Chairpersons: Mario Boccadoro (Turin, IT), Stephen Jolles (Cardiff, UK)		
11.20 - 11.45	Cellular therapies for difficult-to-treat patients  Massimo Martino (Reggio Calabria, IT)		

11.45 - 12.10	Treatment of secondary immunodeficiency and infections in multiple myeloma Stephen Jolles (Cardiff, UK)
12.10 - 12.35	Monoclonal gammopathies of clinical significance  Daniele Derudas (Cagliari, IT)
12.35 - 13.00	Secondary primary malignancies in multiple myeloma  Graham H. Jackson (Newcastle, UK)
13.00 - 14.30	Lunch
14.30 - 15.00	Keynote Lecture Chairperson: Franco Dammacco (Bari, IT)
	CAR-T and Beyond in multiple myeloma  Nizar Jacques Bahlis (Calgary, CAN)
15.00 – 16.40	Workshop 5 First Line Therapy Chairpersons: Salomon Manier (Lille, FR), Pellegrino Musto (Bari, IT)
15.00-15.25	New evidence on induction therapy in transplantable patients  Alessandro Corso (Legnano, IT)
15.25-15.50	Upfront therapy in transplantable patients: can we develop a personalized strategy?  Francesca Gay (Turin, IT)
15.50-16.15	How I treat high-risk myeloma Paola Tacchetti (Bologna, IT)
16.15-16.40	Special problems in the management of elderly patients with multiple myeloma Salomon Manier (Lille, FR)
16.40-17.00	Coffee break
17.00 - 19.10	Workshop 6 Relapsed/Refractory Myeloma Chairpersons: Roberto Ria (Bari, IT), Fredrik Schjesvold (Oslo, NO)
17.00 - 17.25	New strategies for first relapsed patients  Ciro Botta (Palermo, IT)

17.25 - 17.50	Over the second relapse Alessandra Romano (Catania, IT)	
17.50 - 18.15	Unmet medical need for lenalidomide refractory myeloma patients  Javier de la Rubia Comos (Valencia, ES)	
18.15 - 18.40	New combination of anti-CD38 monoclonal antibodies  Fredrik Schjesvold (Oslo, NO)	
18.40 - 19.05	MRD-guided therapeutic strategies  Roberto Mina (Turin, IT)	
Dinner		
Saturday, November 9, 2024		
08.30 - 11.00	Workshop 7 Newest Drugs and Strategies Chairpersons: Shaji Kumar (Rochester, USA), Thomas Lund (Odense, DK)	
08.30 - 08.55	Development of new clinical trial in multiple myeloma  Shaji Kumar (Rochester, USA)	
08.55 - 09.20	Pathway-directed therapy in multiple myeloma Niels Weinhold (Heidelberg, D)	
09.20 – 09.45	Selinexor therapy for multiple myeloma Claudio Cerchione (Meldola, IT)	
09.45 - 10.10	CelMod a new treatment of relapsed/refractory disease TBD	
10.10 - 10.35	Targeting B cell maturation antigen (BCMA) in multiple myeloma Hermann Einsele (Würzburg, D)	
10.35 - 11.00	Emerging antigen target for multiple myeloma immunotherapy  Benedetto Bruno (Turin, IT)	
11.00-11.30	Coffee break	

#### 11.30-13.10 Workshop 8

**Plasma Cell Dyscrasias** 

Chairpersons: Alessandro Corso (Legnano, IT), Hermann Einsele (Würzburg, D)

11.30 - 11.55 Molecular classification, diagnosis, and evidenced-based treatment of plasma cell leukaemia

Thomas Lund (Odense, DK)

11.55 - 12.20 Extramedullary myeloma

Meral Beksac (Ankara, TR)

12.20 - 12.45 Current approach to Waldenström macroglobulinemia Marzia Varettoni (Pavia, Italy)

12.45 - 13.10 New strategies for insoluble organ-deposited amyloid depletion **Paolo Milani (Pavia, IT)** 

13.10 - 13.25 Closing Remarks

Angelo Vacca, Roberto Ria

Congress Closure and CME questionnaire